US EditionNyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Nyxoah (NASDAQ:NYXH)
CMS increased Medicare payments for Genio hypoglossal nerve stimulation implants by up to 58%, enhancing hospital and surgical center adoption prospects, effective January 2026.
- CMS finalized its CY2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgery Center Rule, assigning CPT Code 64568 to New Technology Ambulatory Payment Classification 1580, effective January 1, 2026.
- As part of the CY2026 HOPPS and ASC package, the updates apply uniformly to all procedures billed under CPT Code 64568, including Genio® hypoglossal nerve stimulation implants in hospital outpatient departments and ambulatory surgical centers.
- The final rule sets new facility payments for CPT 64568, increasing Hospital Outpatient Department reimbursement to approximately $1,580 and Ambulatory Surgery Centers to $42,373, effective January 1, 2026.
- Higher ASC payments could enable site-of-service diversification, supporting broader adoption and increased throughput across Hospitals and Ambulatory Surgical Centers for the Genio® system among Medicare patients.
- Looking ahead, Nyxoah noted its recent regulatory progress and study outcomes, including FDA approval in August 2025 and IPOs on Euronext Brussels and Nasdaq, but cautioned forward-looking statements carry risks.
16 Articles
16 Articles
Globe Newswire
The Manila TimesNyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive...
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Nyxoah (NASDAQ:NYXH)
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treat…
MicroTransponder Announces Positive Medicare Payment Change for Vivistim® Procedure
Effective January 1, 2026, the Vivistim® procedure is assigned to New Technology Ambulatory Payment Classification 1580, with an associated national average payment of approximately $45,000
CMS Announces Significant Process Changes for 2026 Program Audits
The Centers for Medicare & Medicaid Services (CMS) has released notice that they will continue using the Final Audit Protocols for the Medicare Part C and Part D Program Audits and the Industry-Wide Part C Timeliness Monitoring Project; however, they have made some significant process changes. The updates reflect CMS’s continued shift toward emphasizing the member experience throughout the entire healthcare journey with the plan. CMS Audit Proce…
MicroTransponder Announces Positive Medicare Payment Change for Vivistim® Procedure
Effective January 1, 2026, the Vivistim® procedure is assigned to New Technology Ambulatory Payment Classification 1580, with an associated national average payment of approximately $45,000
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
